Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Algentech is a private French green biotech company focused on synthetic biology and plant-based bioproduction. The company uses proprietary chloroplast engineering, genome-editing, and self-replicating minichromosome technologies to turn plants into green factories for the production of high-value biomolecules and active ingredients. Its platform is positioned for multisector applications spanning pharmaceuticals, cosmetics, food, agritech, and industrial biobased products rather than a traditional human therapeutic pipeline. Publicly described products include melanin, antimicrobial proteins, and linear and circular RNAs, alongside partner-facing proof-of-concept and licensing offerings. Algentech appears to operate primarily as a platform and ingredient/technology company rather than a clinical-stage drug developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Algentech.